# FDA Adds GLP-1 Blindness Warning

> FDA requires new warnings for GLP-1 drugs after rare vision loss risk found.
- Title: FDA Adds GLP-1 Blindness Warning · PolitiFact | Shortify
- Summary: FDA requires new warnings for GLP-1 drugs after rare vision loss risk found. FDA mandates updated warnings for GLP-1 medications due to higher risk of…
- Keywords: fda, glp-1, blindness, optic nerve, vision loss, semaglutide, wegovy, zepbound, naion, diabetes treatment, weight loss drugs, PolitiFact
- Source: PolitiFact — https://politifact.com/article/2026/nov/12/fda-glp1-warning-blindness-vision-loss-naion
- Author: Grace Abels
- Published: 2026-11-12T17:04:45+00:00
- Read time: 1 min
- Topics: fda, glp-1, blindness, optic nerve, vision loss, semaglutide, wegovy, zepbound, naion, diabetes treatment, weight loss drugs, politics
## FDA new warning
The Food and Drug Administration will require updated warnings for GLP-1 medications about a rare optic nerve condition that can cause partial vision loss.
## Risk found in study
Independent research and the FDA’s own review found patients taking GLP-1s may have a higher risk for the condition than people who don’t.
## Study results
Among 134,200 patients in the FDA’s clinical trial analysis, 15 cases were detected: 10 among GLP-1 users and five among placebo users.
## Condition explained
Nonarteritic anterior ischemic optic neuropathy causes painless sudden vision loss in part of the field of view and affects one eye initially.
## Research triggered FDA action
A 2024 study found 17 out of 169 diabetic patients on semaglutide developed the vision loss condition versus four times the rate in non-users.
## FDA meta-analysis
The FDA reviewed 126 clinical trials involving 134,253 patients and found 10 probable cases of vision loss in GLP-1 users versus five in placebo groups.
## Expert opinion
Dr. Scott Kahan says the risk is real but rare and that the new warning won’t change prescribing but may improve patient conversations.
## Patient advice
Patients should discuss preexisting eye conditions with doctors and not stop GLP-1s without medical guidance.
## Key takeaway

FDA mandates updated warnings for GLP-1 medications due to higher risk of partial blindness from optic nerve condition.